NRX Pharmaceuticals
Yahoo Finance • 17 days ago
NRx Subsidiary HOPE Begins Patient Treatment Using AI-Guided TMS Systems
(RTTNews) - NRx Pharmaceuticals, Inc. (NRXP), a clinical-stage biopharmaceutical company, announced that its subsidiary HOPE Therapeutics, Inc. has initiated treatment of patients with major depressive disorder using FDA-cleared Zeta TMS N... Full story
Yahoo Finance • 21 days ago
NRx Pharmaceuticals's NRX-101 Wins FDA Approval For Intermediate Population Expanded Access Protocol
(RTTNews) - NRx Pharmaceuticals, Inc. (NRXP), Monday announced that the Food and Drug Administration has approved an Intermediate Population Expanded Access Protocol for the use of NRX-101, a fixed dose combination of D-cycloserine and lur... Full story
Yahoo Finance • last month
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
WILMINGTON, Del., June 04, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced un... Full story
Yahoo Finance • last month
NRx Announces Proposed Public Offering; Stock Down
(RTTNews) - NRx Pharmaceuticals (NRXP), a clinical-stage biopharmaceutical company, on Tuesday announced a proposed underwritten public offering. Following the announcement, shares dipped by 22% in the overnight trade on Wednesday. The c... Full story
Yahoo Finance • last month
NRx Pharmaceuticals announces proposed public stock offering
* NRx Pharmaceuticals (NRXP [https://seekingalpha.com/symbol/NRXP]) said [https://seekingalpha.com/pr/20537823-nrx-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock] Tuesday it plans to launch an underwritten public... Full story
Yahoo Finance • 2 months ago
My Top 3 Biotech Stocks for May 2026
Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large pharmaceutical companies are sitting on billio... Full story
Yahoo Finance • 2 months ago
NRx Pharmaceuticals Q1 Earnings Call Highlights
Key Points Interested in NRx Pharmaceuticals, Inc.? Here are five stocks we like better. KETAFREE moved closer to a potential summer 2026 approval after the FDA issued mostly minor review comments, and NRx said it has already begun commer... Full story
Yahoo Finance • 2 months ago
Here are the major earnings before the open Monday
Major earnings expected before the bell on Monday include: * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * iQIYI (IQ [https://seekingalpha.com/symbol/IQ]) * Ryanair Holdings plc (RYAAY [https://seekingalpha.com/symbol/RYAAY]... Full story
Yahoo Finance • 2 months ago
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More
Quick Read: The April inflation spike hit stocks hard, as only the Dow Jones Industrial Average finished Tuesday modestly higher. With inflation at its highest level in over 3 years, it’s unlikely the Federal Reserve will cut interest rat... Full story
Yahoo Finance • 3 months ago
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Tilray Brands Global Push is Paying Off as International Cannabis Growth Drove Record Q3 Revenue Charlotte’s Web Strengthened Balance Sheet as British American Tobacco Deepened Stake Amid Strategic Growth Pu... Full story
Yahoo Finance • 4 months ago
NRx Pharmaceuticals Q4 Earnings Call Highlights
NRx Pharmaceuticals logo 5 Biotech stocks tapping into unmet mental health treatment needs NRx Pharmaceuticals (NASDAQ:NRXP) executives used the company’s fourth-quarter 2025 results call to outline what they described as a “pivotal and... Full story
Yahoo Finance • 4 months ago
NRx Pharmaceuticals Wraps Virtual Annual Meeting, Eyes Pivotal 2025 Earnings Call Ahead
NRx Pharmaceuticals logo Key Points 2025 described as "extraordinarily pivotal": NRx said it is "in the FDA" with at least one drug it hopes could be approved this year and is operating revenue-generating clinics treating patients daily.... Full story
Yahoo Finance • 4 months ago
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
Featured Companies Include FreeCast (NASDAQ:CAST), KLED.ai, Lantern Pharma (NASDAQ:LTRN), and BlackBarn Restaurant NEW YORK CITY, NY / ACCESS Newswire / March 21, 2026 / New to The Street, one of the longest-running U.S. and international... Full story
Yahoo Finance • 4 months ago
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
The bipolar depression market is anticipated to increase during the forecast period (2026–2036), owing to the rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics... Full story
Yahoo Finance • 4 months ago
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the scien... Full story
Yahoo Finance • 7 months ago
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal response achieved by Transcranial Magnetic Stimulation (TMS).NRx has amended its Investigational New Drug filing f... Full story
Yahoo Finance • 7 months ago
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is “substantially complete” and received for review. Assigned GDUFA goal date is July 29, 2026.NRx has applied to FDA for use of KETAFREE™ as a proprietary product name,... Full story
Yahoo Finance • 7 months ago
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a corporate update confere... Full story
Yahoo Finance • 7 months ago
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference
WILMINGTON, Del., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, the “Company”, “NRx”), a clinical-stage biopharmaceutical company and HOPE Therapeutics, an interventional psychiatry network owned by NRx, toda... Full story
Yahoo Finance • 8 months ago
NRx Pharmaceuticals outlines rapid clinic expansion and targets 6 or more locations by year-end 2025 amid new depression treatment advances
Earnings Call Insights: NRx Pharmaceuticals (NRXP) Q3 2025 MANAGEMENT VIEW * Matthew Duffy, Chief Business Officer & Co-CEO of Hope Therapeutics, opened the call stating, "Since the beginning of the third quarter, NRx has made transfor... Full story